CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 557-562

  Thomson, Kenneth S ^a   Moland, Ellen Smith ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lactams; Carbapenems; Imipenem; Meropenem

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CS 023; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OXACILLIN; PENICILLIN G; R 115685; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; STANDARDIZATION; STAPHYLOCOCCUS; UNITED STATES;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; PENICILLIN RESISTANCE; PENICILLINS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; UNITED STATES;

EID: 4444266407     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh328     Document Type: Article

References (10)

1. Sanders, C. C. & Thomson, K. S. (1992). Other β-lactam antibiotics. In Infectious Diseases, 2nd edn. (Gorbach, S., Bartlett, J. & Blacklow, N. R. Eds), pp. 197-204. W. B. Saunders Company, Philadelphia, PA, USA.
2. Livermore, D. M., Oakton, K. J., Carter, M. W. et al. (2001). Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrobial Agents and Chemotherapy 45, 2831-7.
3. Sader, H. S., Cerbara, E. F., Luz, D. et al. (1999). Evaluation of the cephalosporins, cefepime, cefpirome and ceftazidime, against clinical isolates of imipenem-resistant Pseudomonas aeruginosa. Brazilian Journal of Infectious Diseases 3, 231-7.
4. Kawamoto, I., Shimoji, Y., Kanno, O. et al. (2003). Synthesis and structure - activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. Journal of Antibiotics (Tokyo) 56, 565-79.
5. Fukuoka, T., Koga, T., Ishii, C. et al. (2002). Antibacterial activity of CS-023 against MRSA and Pseudomonas aeruginosa. In Program and Abstracts of the Forty-second interscience Conference on Antimicrobial Agents and Chemotherapyc, 22-30 September 2002, San Diego, CA, USA. Abstract F-324, p. 172. American Society for Microbiology, Washington, DC, USA.
6. Rennecke, J., Hirota, T., Shibayama, T. at al. (2002). Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers. In Program and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, 22-30 September 2002, San Diego, CA, USA. Abstract F-327, p. 173. American Society for Microbiology, Washington, DC, USA.
7. National Committee for Clinical Laboratory Standards (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard, M7-A5. NCCLS, Wayne, PA, USA.
8. Fukuoka, T., Puechler, K., Rennecke, J. at al. (2002). In vitro activity of CS-023 against European clinical relevant bacterial isolates. In Program and Abstracts of the Forty-second interscience Conference on Antimicrobial Agents and Chemotherapy, 22-30 September 2002, San Diego, CA, USA. Abstract F-326, p. 172. American Society for Microbiology, Washington, DC, USA.
9. Nagano, R., Shibata, K., Adachi, Y. at al. (2000). In vitro activities of novel trans-3, 5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 44, 489-95.
10. Ueda, Y. & Sunagawa, M. (2003). In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 47, 2471-80.